An Open-Label Study to Evaluate Retreatment With LIPO-202
NCT02397525
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
150
Enrollment
INDUSTRY
Sponsor class
Conditions
Central Abdominal Bulging
Interventions
DRUG:
LIPO-202
Sponsor
Neothetics, Inc